alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 1304.21 General requirements for continuing records. ( a ) Every registrant required to keep records pursuant to § 1304.03 shall maintain, on a current basis, a complete and accurate record of each substance manufactured, imported, received, sold, delivered, exported, or otherwise disposed of by him/her, and each inner liner, sealed inner liner, and unused and returned mail-back package, except that no registrant shall be required to maintain a perpetual inventory.
( b ) Separate records shall be maintained by a registrant for each registered location except as provided in § 1304.04 (a). In the event controlled substances are in the possession or under the control of a registrant at a location for which he is not registered, the substances shall be included in the records of the registered location to which they are subject to control or to which the person possessing the substance is responsible.
( c ) Separate records shall be maintained by a registrant for each independent activity and collection activity for which he/she is registered or authorized, except as provided in § 1304.22(d).
( d ) In recording dates of receipt, distribution, other transfers, or destruction, the date on which the controlled substances are actually received, distributed, otherwise transferred, or destroyed will be used as the date of receipt, distribution, transfer, or destruction (*e.g.,* invoices or packing slips, or DEA Form 41). In maintaining records concerning imports and exports, the registrant must record the anticipated date of release by a customs official for permit applications and declarations and the date on which the controlled substances are released by a customs officer at the port of entry or port of export for return information.
( e ) *Record of destruction.* In addition to any other recordkeeping requirements, any registered person that destroys a controlled substance pursuant to § 1317.95(d), or causes the destruction of a controlled substance pursuant to § 1317.95(c), shall maintain a record of destruction on a DEA Form 41. The records shall be complete and accurate, and include the name and signature of the two employees who witnessed the destruction. Except, destruction of a controlled substance dispensed by a practitioner for immediate administration at the practitioner's registered location, when the substance is not fully exhausted (e.g., some of the substance remains in a vial, tube, or syringe after administration but cannot or may not be further utilized), shall be properly recorded in accordance with § 1304.22(c), and such record need not be maintained on a DEA Form 41.
[36 FR 7792, Apr. 24, 1971, as amended at 36 FR 13386, July 21, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973, as amended at 62 FR 13960, Mar. 24, 1997; 79 FR 53563, Sept. 9, 2014; 81 FR 97020, Dec. 30, 2016]
EX-10.1



 EXHIBIT 10.1 

BELMONT SAVINGS BANK 

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 

APPENDIX A-1 

Except as otherwise defined in this Appendix, the terms used herein shall have the meaning(s) ascribed to them in the Belmont Savings Bank
Supplemental Executive Retirement Plan (“Plan”), to which this Appendix, as amended from time to time, is appended and into which this Appendix is incorporated by reference. 

Participant’s Benefit Percentage: 20% of Participant’s Final Average Compensation (as defined in the Plan), multiplied by the
Participant’s Vested Percentage, as set forth herein: 
  

							
	Participant Name	  	Date of Hire	  	Years of Service	  	Vested Percentage
	 Robert M. Mahoney
	  	May 12, 2010	  	0-4	  	0%
		  		  	5 or more	  	100%

 Notwithstanding the foregoing, if prior to the completion of five (5) Years of Service, the Participant either is
terminated by the Bank without Cause or resigns for Good Reason, the Participant’s “Benefit Percentage” shall be multiplied by the following: 
  

			
	Years of Service	  	Vested Percentage
	 Less than 1
	  	20%
	 1
	  	40%
	 2
	  	60%
	 3
	  	80%
	 4
	  	100%


  
 A-1
EXHIBIT 10.53
                              Note to Exhibit 10.53



         The following Indenture Supplement is substantially identical in all
material respects to five additional Indenture Supplements except as follows:

<TABLE>
<CAPTION>

Owner Participant                                       Date                                    Aircraft (Tail No.)
-----------------                                       ----
<S>                                                     <C>                                     <C>
NCC Charlie Company*                                    September 10, 1998*                     N575ML*
NCC Charlie Company                                     September 10, 1998                      N576ML
General Electric Capital Corporation                    November 10, 1998                       N577ML
General Electric Capital Corporation                    November 10, 1998                       N578ML
Castle Harbour Leasing Inc.                             December 10, 1998                       N579ML                        
NCC Charlie Company                                     January 25, 1999                        N580ML                       
</TABLE>



------------------

*   Filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the
    quarter ended September 30, 1998.
<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                    ----------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


      Date of Report (Date of earliest event reported): September 24, 1997


                           MIDCOM Communications Inc.
             (Exact name of registrant as specified in its charter)


                                   Washington
         (State or other jurisdiction of incorporation or organization)


<TABLE>
 <S>                                       <C>
         000-26118                                     91-1438806
         ---------                                     ----------
 (Commission File Number)                  (I.R.S Employer Identification No.)
</TABLE>


                           26899 Northwestern Highway
                                   Suite 120
                           Southfield, Michigan 48034
                   -------------------------------------------
                    (Address of principal executive offices)


                                 (248) 304-1780
                                 --------------
              (Registrant's telephone number, including area code)





<PAGE>   2
Item 5.  Other Events

         On August 13, 1997 MIDCOM Communications Inc. (the "Company") issued a
press release announcing that it has signed a definitive merger agreement with
Phoenix Network, Inc. The text of that press release is included with this
report as Exhibit 99.1.


Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

         (c)  Exhibits

         99.1     Press release dated August 13, 1997.



                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        MIDCOM COMMUNICATIONS INC.


         Dated: September 24, 1997          By: /s/ Steven P. Goldman
                                            ---------------------
                                            Steven P. Goldman
                                            Vice President and General Counsel



<PAGE>   3
                           MIDCOM COMMUNICATIONS INC.
                                 EXHIBIT INDEX

<TABLE>
<CAPTION>

        <S>     <C>
        99.1    Press release dated August 13, 1997.
</TABLE>
**Exhibit31.2**

**CERTIFICATION OF PRINCIPALFINANCIAL OFFICER**

I, Douglas W.Cowan, certify that:

1. I have reviewedthis annual report on Form 10-K of Retractable Technologies, Inc.;

2. Based on myknowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

3. Based on myknowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financialcondition, results of operations, and cash flows of the registrant as of, andfor, the periods presented in this report;

a)              Designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

b)             Evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport, based on such evaluation;

c)              Disclosed in thisreport any changes in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal controls over financial reporting; and

5. The registrant’s other certifying officers and Ihave disclosed, based on our most recent evaluation of internal control overfinancial reporting, to the registrant’s auditors and the audit committee ofthe registrant’s board of directors (or persons performing the equivalentfunctions):

a) All significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize, and reportfinancial information; and

b) Any fraud,whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.
| Date:  April 2, 2007 |   |                    |
|---------------------------|--------|-------------------------|
|                      |   | /s/ Douglas W. Cowan    |
|                      |   | DOUGLAS W. COWAN        |
|                      |   | VICE PRESIDENT AND      |
|                      |   | CHIEF FINANCIAL OFFICER |
|                      |   |                    |

 

----
<TABLE> <S> <C>


<ARTICLE> 5

<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                    DEC-31-1996
<PERIOD-END>                         DEC-31-1996
<CASH>                                   727,931
<SECURITIES>                                   0                       
<RECEIVABLES>                             69,302
<ALLOWANCES>                                   0
<INVENTORY>                               34,051
<CURRENT-ASSETS>                         853,453
<PP&E>                                    20,922
<DEPRECIATION>                             4,304
<TOTAL-ASSETS>                         1,106,625
<CURRENT-LIABILITIES>                    358,018
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                   4,520
<OTHER-SE>                               744,087
<TOTAL-LIABILITY-AND-EQUITY>           1,106,625
<SALES>                                  553,566
<TOTAL-REVENUES>                         553,566
<CGS>                                  2,340,575
<TOTAL-COSTS>                          2,340,575
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                          91,580
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                       (5,326,874)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                   (5,326,874)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                          (5,326,874)
<EPS-PRIMARY>                              (1.41)
<EPS-DILUTED>                              (1.41)

        

</TABLE>
§ 520.1660c Oxytetracycline tablets. ( a ) *Specifications.* Each tablet contains 250 or 500 milligrams (mg) oxytetracycline hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Tolerances.* See § 556.500 of this chapter.
( d ) *Conditions of use in beef and dairy cattle* — ( 1 ) *Amounts.* 10 mg per pound of body weight every 12 hours for treatment; 5 mg per pound of body weight every 12 hours for control.
( 2 ) *Indications for use.* For treatment and control of bacterial enteritis caused by *Salmonella typhimurium* and *Escherichia coli* (colibacillosis) and bacterial pneumonia (shipping fever complex, pasteurellosis) caused by *Pasteurella multocida.*
( 3 ) *Limitations.* Discontinue treatment 7 days prior to slaughter. Not for use in lactating dairy cattle. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[46 FR 32440, June 23, 1981, as amended at 50 FR 1045, Jan. 9, 1985; 63 FR 70334, Dec. 21, 1998; 70 FR 16394, Apr. 4, 2005; 78 FR 28825, May 20, 2014; 88 FR 14897, Mar. 10, 2023; 88 FR 55563, Aug. 16, 2023]
38388.

#### CITY OF BAINBRIDGE v. YOUNGBLOOD.

Decided June 29, 1960

Rehearing denied July 14,1960.

*198
      *Conger •& Conger,*for plaintiff in error.

*Vance Custer, Charles A. Kirbo, Harold Lambert,*contra.

Gardner, Presiding Judge.

1. It is conceded that under *Code*§ 105-603 the plaintiff would not be entitled to recover if she could have avoided the injury by the use of ordinary care. See *White v. City of Manchester,*92 Ga. App. 642 (89 S. E. 2d 581); and *Lane Drug Stores v. Story,*72 Ga. App. 886 (35 S. E. 2d 472). The street where this accident occurred was in a very dilapidated condition as shown by pictures referred to hereinabove. Even if the plaintiff could possibly have known that the street was in a bad state of repair, when we look at the pictures shown in the record, it is comprehensible to us that she could not very well have walked across this expanse of defective sidewalk without being injured, even though she might have thought she could have. It is the duty of a municipality to keep streets and sidewalks in a reasonably safe condition for travel in the ordinary mode.

The jury in.the instant case determined that the defendant was negligent in failing to maintain the sidewalks in a reasonably safe condition. There are many, many cases holding that, when a municipality fails in this respect, it is liable for injuries sustained by a person who is using reasonable care for his or her own safety.

When a jury has passed on the facts in a case the appellate courts are constrained not to reverse the verdict of the jury. In this respect the Supreme Court said in *Ingram v. State,*204 Ga. 164, 184 (48 S. E. 2d 891): “In passing on the general grounds of a motion for new trial, this court passes not on the weight but on the sufficiency of the evidence. It is our duty to determine whether the verdict as rendered can be sustained under any reasonable view taken of the proof submitted to the jury. We are not called upon to say whether, had we been in the place of the jury, we might have found the accused guilty of a lesser offense. It was the province of the jury, and theirs alone, to put their appraisal upon the proofs submitted to them.”

*199It is never error for a trial court to refuse to direct a verdict. It is clear to us that no error was committed in this respect in the case at bar. The evidence is clear and conclusive that the defendant was negligent in maintaining the sidewalks. There is no evidence to show that the plaintiff did not exercise ordinary care for her own safety. There is no merit to the contention that the trial court erred in overruling the motion for a judgment notwithstanding the verdict. Failure to grant a motion for a judgment notwithstanding the verdict is reversible error only where the evidence shows conclusively that the jury arrived at an obviously incorrect verdict.

The overruling of the motion for new trial shows no cause for reversal.

*Judgment affirmed.*

*Townsend, Carlisle and Frankum, JJ., concur.*
§ 520.452 Clenbuterol syrup. ( a ) *Specifications.* Each milliliter contains 72.5 micrograms of clenbuterol hydrochloride.
( b ) *Sponsor.* See 000010 in § 510.600(c) of this chapter.
( c ) [Reserved]
( d ) *Conditions of use* — ( 1 ) *Horses* — ( i ) *Amount.* Administer orally twice a day (b.i.d.). Initial dose is 0.5 milliliter per 100 pounds body weight (0.8 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1 milliliter per 100 pounds (1.6 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1.5 milliliters per 100 pounds (2.4 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 2.0 milliliters per 100 pounds (3.2 micrograms per kilogram) for 3 days (6 treatments). If no improvement, horse is nonresponder to clenbuterol and treatment should be discontinued.
( ii ) *Indications for use.* Indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).
( iii ) *Limitations.* Treat at effective dose for 30 days. At the end of the 30-day treatment period, drug should be withdrawn. If signs return, the 30-day treatment period may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated. The effect of this drug on breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended. Federal law prohibits the extralabel use of this drug in food animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[63 FR 41419, Aug. 4, 1998]
I 

118TH CONGRESS 

2D SESSION H. R. 7329 

To amend title 5, United States Code, to establish Election Day as a legal 

public holiday, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 13, 2024 

Ms. ESHOO (for herself, Mrs. WATSON COLEMAN, Ms. NORTON, Mr. GOLDMAN of New York, Ms. WILLIAMS of Georgia, Mr. SCHIFF, Mr. MEEKS, 

Ms. VELA ́ZQUEZ, Ms. LEE of California, Mr. PHILLIPS, Mr. MOULTON, 

Mr. THOMPSON of Mississippi, Mr. JOHNSON of Georgia, Ms. CLARKE of 

New York, Mr. GARAMENDI, Mr. RUPPERSBERGER, Mr. CARSON, Mr. 

GRIJALVA, Mr. CASTEN, Mr. LIEU, Mr. ESPAILLAT, and Mr. BLUMENAUER) introduced the following bill; which was referred to the Committee on Oversight and Accountability 

A BILL 

To amend title 5, United States Code, to establish Election 

Day as a legal public holiday, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Election Day Holiday 

5 Act of 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7329 IH

1 SEC. 2. ELECTION DAY AS A LEGAL PUBLIC HOLIDAY. 

2 Section 6103(a) of title 5, United States Code, is 

3 amended by inserting after the item relating to Columbus 

4 Day the following: 

5 ‘‘Election Day.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 314
Editorial Note: Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

§ 314.97 Supplements and other changes to an approved ANDA. ( a ) *General requirements.* The applicant must comply with the requirements of §§ 314.70 and 314.71 regarding the submission of supplemental ANDAs and other changes to an approved ANDA.
( b ) *Different listed drug.* An applicant may not supplement an ANDA to seek approval of a drug referring to a listed drug that is different from the current reference listed drug identified in the ANDA. This paragraph (b) applies if changes are proposed in a supplement to the ANDA such that the proposed product is a pharmaceutical equivalent to a different listed drug than the reference listed drug identified in the ANDA. A change of reference listed drug must be submitted in a new ANDA. However, notwithstanding the limitation described in this paragraph (b), an applicant may supplement the ANDA to seek approval of a different strength.
[81 FR 69653, Oct. 6, 2016]
#### § 211.173 Laboratory animals.

Animals used in testing components, in-process materials, or drug products for compliance with established specifications shall be maintained and controlled in a manner that assures their suitability for their intended use. They shall be identified, and adequate records shall be maintained showing the history of their use.
§ 556.283 Florfenicol. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of florfenicol is 10 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for florfenicol amine (marker residue) are: ( 1 ) *Cattle.* ( i ) Liver (target tissue): 3.7 ppm.
( ii ) Muscle: 0.3 ppm.
( 2 ) *Swine.* ( i ) Liver (target tissue): 2.5 ppm.
( ii ) Muscle: 0.2 ppm.
( 3 ) *Catfish.* Muscle (target tissue): 1 ppm.
( 4 ) *Freshwater-reared warmwater finfish (other than catfish) and salmonids.* Muscle/skin (target tissue): 1 ppm.
( c ) *Related conditions of use.* See §§ 520.955, 522.955, 522.956, and 558.261 of this chapter.